Journal of Clinical Oncology · 2010 · 49 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyAdjuvant ChemotherapyAdjuvant PharmacotherapyColorectal CancerGastrointestinal Cancer PharmacotherapyBolus RegimensCapecitabine-based TherapyColon Cancer Adjuvant TherapyColorectal Cancer Adjuvant TherapyDisease-free Survival AnalysisDisease-free Survival AssessmentOxaliplatin-based TherapySafety Analysis
3521 Background: Adjuvant capecitabine is at least equivalent to bolus i.v. 5-FU/LV for DFS and overall survival (OS) in stage III colon cancer. NO16968 compared XELOX with bolus i.v. 5-FU/LV (standard regimen at study start) for stage III colon cancer. In a planned safety analysis, XELOX had an acceptable safety profile (Schmoll et al. JCO 2007). In a recent analysis of the ACCENT database, investigators concluded that newer adjuvant regimens are not associated with significant efficacy benefits vs. 5-FU/LV in patients (pts) ≥70 years (McCleary et al. ASCO 2009). We examined DFS across age groups in NO16968 to determine XELOX efficacy in pts ≥70 years. Methods: Pts were randomized to either XELOX (capecitabine 1,000 mg/m2 bid d1–14 + oxaliplatin 130 mg/m2 i.v. d1, q3w ×8) or bolus i.v. 5-FU/LV regimens: Mayo Clinic (LV 20 mg/m2 + 5-FU 425 mg/m2 d1–5, q4w ×6) or Roswell Park (LV 500 mg/m2 + 5-FU 500 mg/m2 d1, w1–6 in 8w cycles × 4). Results: 1,886 pts were randomized between April 2003 and October 2004. 1,864 were evaluable in the previously reported safety analysis. After a median follow-up of 57 months, 1,886 pts are evaluable for DFS (primary endpoint), which was significantly superior for XELOX at 3, 4, and 5 years (Table). Analysis of 3-year DFS in pts <70 and ≥70 years showed a similar advantage of XELOX over 5-FU/LV. Conclusions: XELOX is superior to bolus 5-FU/LV for DFS as adjuvant treatment for stage III colon cancer and these findings confirm the benefits shown with oxaliplatin plus 5-FU combinations in stage III pts. Additionally, efficacy benefits seem to be maintained in pts ≥70 years and differ from the ACCENT meta-analysis and MOSAIC, where no significant benefit was shown with FOLFOX in this age group. It is therefore reasonable to evaluate each pt for XELOX therapy on individual merits, regardless of age. OS data are currently immature; follow-up is ongoing and updates will be reported when available. 3-year DFS 4-year DFS 5-year DFS Total population XELOX 71.0% HR 0.80 68.4% 66.1% 5-FU/LV 67.0% p=0.0045 62.3% 59.8% Analysis by age group <70 years HR 0.79 (95% CI 0.66–0.94) ≥70 years HR 0.87 (95% CI 0.63–1.18) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Merck, Merck Sharpe and Dome, Roche, sanofi-aventis Roche AstraZeneca, Merck, Roche, sanofi-aventis Merck, Roche, sanofi-aventis